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Abstract. Aim: To assess the patterns of recurrence and
clinical outcomes of patients with cervical adenocarcinoma
who underwent neoadjuvant platinum-based chemotherapy
(NACT) followed by radical hysterectomy. Patients and
Methods: Data were retrospectively analyzed for 82 patients
with International Federation of Gynecology and Obstetrics
stage Ib2-IIb cervical adenocarcinoma who underwent this
chemo-surgical treatment. The median follow-up of survivors
was 89 months (range=5-208 months). Results: Pathological
complete response, optimal response and suboptimal response
with intra-cervical residual disease were obtained in five (6%),
10 (12%) and 36 (44%) patients, respectively. Adjuvant
external-beam radiotherapy with or without concurrent
chemotherapy was administered to 47 patients. Nineteen (23%)
out of the 82 patients experienced recurrence after a median
of 12 months (range=5.3-86.8 months). Recurrent disease was
pelvic in 12 (63%) patients, extra-pelvic in five (26%), and
both pelvic and extra-pelvic in two (10%). According to
pathological response, tumor relapsed in 10% of optimal
responders, 14% of sub-optimal responders with intra-cervical
residual disease, and 36% of sub-optimal responders with
extra-cervical residual disease or non-responders. Five-year
recurrence-free and overall survival were 77% and 84%,
respectively. Patients who achieved an optimal response or
sub-optimal response with intra-cervical residual disease had
better 5-year recurrence-free (87% vs. 64%, p=0.017) and
overall (92% vs. 74%, p=0.012) survival than those who had
sub-optimal response with extra-cervical residual disease or
no response. The latter had a 1.441-fold higher risk of
recurrence and a 1.652-fold higher risk of death than those
who obtained an optimal response or a sub-optimal response
with intra-cervical residual disease. Conclusion: NACT
followed by radical hysterectomy may be an option for patients
with stage Ib2-IIb adenocarcinoma of the uterine cervix. 
Concurrent cisplatin-based chemotherapy and radiotherapy
(CCRT) is the standard-of-care for patients with locally
advanced cervical cancer and recent meta-analyses of
randomized trials have confirmed that this therapeutic
approach significantly improves progression-free survival and
overall survival compared to definitive radiotherapy alone (1-
5). Neoadjuvant chemotherapy (NACT) followed by radical
hysterectomy is an interesting alternative to CCRT for
patients with locally advanced cervical cancer, especially for
those with stage Ib2-IIb disease (6-16). A meta-analysis of six
randomized trials, including 1078 patients with early or
locally advanced disease, revealed that NACT followed by
radical hysterectomy significantly reduced the risk of
progression [hazard ratio (HR)=0.75, 95% confidence Interval
(CI)=0.61-0.93, p=0.008] and the risk of death (HR=0.77,
95% CI=0.62-0.96 p=0.02) compared to primary radical
hysterectomy (17). Moreover, a meta-analysis of five
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randomized trials, including 872 patients with locally
advanced cervical cancer, showed that the chemo-surgical
treatment obtained better overall disease-free (HR=0.68, 95%
CI=0.56-0.82), locoregional disease-free (HR=0.68, 95%
CI=0.56-0.82), metastasis-free (HR=0.63, 95% CI=0.52-
0.78), and overall (HR=0.65, 95% CI=0.53-0.80) survival
compared with definitive radiotherapy (18). An European
Organization for Research and Treatment of Cancer (EORTC)
randomized trial is currently comparing NACT plus radical
surgery versus CCRT in patients with stage Ib2, IIa or IIb
cervical cancer (EORTC protocol 55994).
Adenocarcinoma of the uterine cervix represents 10-20%
of all cervical cancer cases, but its relative and absolute
incidence has increased over the past four decades (19, 20).
Some authors have reported that cervical adenocarcinoma
has a worse prognosis than cervical squamous cell carcinoma
(12, 21-27).
Clinical studies regarding NACT followed by radical
surgery have usually included patients with cervical squamous
cell carcinoma (6-8, 11, 13, 15) or with cervical carcinoma of
any histological type mainly consisting of squamous cell
carcinoma (9, 12, 14, 16, 28-35), whereas very few studies
have selectively investigated this therapeutic approach in
patients with cervical adenocarcinoma (36-42). Some authors
suggested that non-squamous carcinoma was associated with
a lower response rate to NACT than squamous cell carcinoma
(14, 28, 29), but others did not confirm these observations (30,
31, 33, 34). 
The aim of this retrospective multicenter study was to
assess the patterns of recurrence and the clinical outcomes
of patients with cervical adenocarcinoma who underwent
platinum-based NACT followed by radical hysterectomy.
Patients and Methods 
This retrospective study was conducted on 82 patients with
International Federation of Gynecology and Obstetrics (FIGO) stage
Ib2-IIb cervical adenocarcinoma who underwent platinum-based
NACT followed by radical hysterectomy with pelvic
lymphadenectomy at the Department of Gynecology and Obstetrics of
the University of Pisa and Turin between 1992 and 2014, and at the
Department of Gynecology and Obstetrics of the University of Brescia
and at the Department of Gynecologic Oncology of the European
Institute of Milan between 1999 and 2014. Most of these patients had
been included in a prior retrospective study of our cooperative group
(16). Platinum-based NACT followed by surgery was the common
treatment strategy for patients with stage Ib2–IIb disease, maximum
age of 70 years and good performance status at our Oncologic Centers.
All women of the present retrospective investigation provided written
informed consent for this treatment modality. Patients who did not
complete the planned cycles of NACT or who did not undergo radical
surgery after NACT because of progressive disease or poor general
condition were not included in the present study. 
The hospital records, including surgical notes and pathological
reports, of the women were collected using a common form with
standardized items and a common database. Patient characteristics at
initial diagnosis (date, age, FIGO stage, histological grade, tumor
size), NACT regimen, type of radical hysterectomy, and pathological
responses on surgical specimens were reported for each case.
Pre-treatment assessment included history, physical examination,
vaginal-pelvic examination, colposcopy, biopsy, complete blood
analysis, chest X-ray, and, in the last decade, pelvic magnetic
resonance imaging (MRI). Cystoscopy or proctoscopy were
performed if there was a clinical or CT/MRI suspicion of bladder
or rectal involvement. Further investigation was performed when
indicated.
Physical and vaginal-pelvic examination and abdominal-pelvic
CT scan were repeated 3-4 weeks after the completion of
chemotherapy. All patients underwent type II-III radical
hysterectomy with pelvic lymphadenectomy within 3-6 weeks after
the last cycle of chemotherapy.
Clinical response to NACT was determined using the Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (43).
Pathological responses were assessed as follows. Complete
response was defined as the complete disappearance of the tumor in
the cervix with negative nodes; optimal partial response was defined
as persistent residual disease with <3 mm stromal invasion including
in situ carcinoma on the surgical specimen and negative nodes; sub-
optimal response with intra-cervical residual disease was defined as
persistent residual disease with >3 mm stromal invasion within the
cervix and negative nodes; sub-optimal response with extra-cervical
residual disease consisted of positive nodes regardless of parametria
and surgical margins, as well as positive parametria of surgical
margins with negative nodes. The pathological optimal response rate
was the sum of complete and optimal partial response rates. 
Postoperative management was individually established on the
basis of histological findings on surgical specimen, patient age and
general conditions, after an exhaustive discussion with the patient
by a multidisciplinary team.
The patients were periodically followed-up with clinical and
radiological examinations until they died or until May 2017. The
median follow-up of survivors was 89 months (range=5-208 months).
Statistical analysis. SPSS ver.13 (SPSS Inc., Chicago IL, USA) was
used for computations.
The time from the first cycle of NACT to the detection of
recurrence was defined as recurrence-free survival. The time from
the first cycle of NACT to death or last observation was defined as
overall survival. 
The cumulative probabilities of recurrence-free and overall
survival were estimated by the product-limit method. The log-rank
test was used to compare the homogeneity of recurrence-free
survival and survival functions across strata defined by categories
of prognostic variables. A multiple regression analysis based on the
Cox proportional hazards model was used to jointly test the relative
importance of variables as predictors of recurrence-free and overall
survival.
Results
Median age of patients at diagnosis was 46 years (range=23
-68 years). FIGO stage was Ib2 in 53 patients (65%), IIa in
10 (12%), and IIb in 19 (23%). Tumor size was ≤5 cm in 36
patients (44%), >5 cm in 39 (48%), and not specified in
seven. Histological grade was well (G1) or moderately (G2)
differentiated in 34 patients (41%), poorly differentiated (G3)
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in 35 (43%), and not specified in 13. NACT consisted of:
epidoxorubicin (80 mg/m2 day 1), paclitaxel (175 mg/m2 day
1) and cisplatin (75 mg/m2 day 2) (TEP regimen) every 3
weeks for three cycles in 53 patients (64.6%); ifosfamide (5
g/m2 + mesna 5 g/m2 24-hour continuous infusion day 1),
paclitaxel (175 mg/m2 day 2) and cisplatin (75 mg/m2 day
2) every 3 weeks for three cycles in nine (11.0%); paclitaxel
(175 mg/m2) and cisplatin (75 mg/m2) every 3 weeks for
three cycles in six (7.3%); paclitaxel (80 mg/m2) and
carboplatin [area under curve (AUC)=2] every week for six
cycles in six (7.3%); epidoxorubicin (80 mg/m2) and
cisplatin (75 mg/m2) every 3 weeks for three cycles in three
(3.7%); and other platinum-based chemotherapy in five
(6.1%). Radical hysterectomy according to Piver and
Rutledge was of type 3 and type 2 in 66 (80%) and 16 (20%)
patients, respectively. 
A clinical complete response and a partial response were
achieved by nine and 58 patients, respectively, with a clinical
overall response rate of 82%. 
As far as pathological response is concerned, a complete
response and an optimal partial response were obtained by
five patients each, with an optimal response rate of 12%.
Thirty-six patients (44%) had a sub-optimal response with
intra-cervical residual disease, 24 (29%) had a sub-optimal
response with extra-cervical residual disease, and 12 (15%)
had a stable disease (non-responders). 
Post-operative treatment was as follows. Of the 10 optimal
responders, five received additional cycles of chemotherapy
with the induction regimen, two received brachytherapy, and
three had no further therapy. Of the 36 sub-optimal
responders with intra-cervical residual disease, five received
additional cycles of chemotherapy with the induction
regimen, 15 (42%) underwent CCRT or external beam
radiotherapy with or without brachytherapy, one received
brachytherapy, and 15 had no further treatment. 
Of the 36 sub-optimal responders with extra-cervical
residual disease or no response, two received additional cycles
of chemotherapy with the induction regimen, 32 (89%)
underwent CCRT or external beam radiotherapy with or
without brachytherapy (one of them with additional irradiation
on the aortic area), and two had no further treatment. 
At the time of the present analysis, 19 patients (23%) had
experienced recurrence after a medianof 12.5 months
(range=5.3 to 86.8 months). Recurrent disease was pelvic in
12 patients (63%), extra-pelvic (aortic or distant) in five
(26%), and both pelvic and extra-pelvic in two (10%).
Median time to recurrence was 13.7 months (range=6.7 to
86.8 months) for those with pelvic failure and 23.5 months
(range=6.3 to 31.8 months) for those with extra-pelvic
failure. The two patients with both pelvic and extra-pelvic
failure experienced recurrence after 5.3 and 9.7 months,
respectively. 
According to pathological response, tumor relapsed in
10% of optimal responders, 14% of the sub-optimal
responders with intra-cervical residual disease, and 36% of
sub-optimal responders with extra-cervical residual disease
or no response (Table I). 
The optimal responder who experienced recurrence
developed pelvic failure. Extra-pelvic relapse, with or
without pelvic failure, was detected in one out of five (20%)
sub-optimal responders with intra-cervical residual disease,
and six out of 13 (46%) sub-optimal responders with extra-
cervical residual disease or non-responders, who developed
recurrent disease, respectively. 
Table II reports the recurrence rates and sites according to
postoperative treatment. 
Adjuvant CCRT or external beam radiotherapy was not
administered to any of the optimal responders, but was given
to 42% of sub-optimal responders with intra-cervical residual
disease, and 89% of sub-optimal responders with extra-
cervical residual disease or non-responders. 
Pelvic failure after adjuvant CCRT or external beam
radiotherapy occurred in three out of 15 (20%) sub-optimal
responders with intra-cervical residual disease and in seven
out of 32 (22%) sub-optimal responders with extra-cervical
residual disease or non-responders. 
At the time of the present analysis, 56 patients (68%) were
alive with no evidence of tumor, three (4%) were alive with
tumor, 16 (19%) had died of tumor, and seven (8%) died of
concurrent disease with no evidence of tumor. Of these latter
seven patients, three were sub-optimal responders with intra-
cervical residual disease, two were sub-optimal responders
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Table I. Recurrence rates and sites according to pathological response.
                                                                                                                                                               Site of recurrence, n
Pathological response                                                                               Patients, n      Pelvic      Extrapelvic      Pelvic + extrapelvic      Overall, n (%)
Overall optimal                                                                                                10                 1                  0                              0                           1 (10%)
Sub-optimal response with intra-cervical residual                                        36                 4                  0                              1                           5 (14%)
Sub-optimal response with extra-cervical residual/non-response                36                 7                  5                              1                         13 (36%)
with extra-cervical residual disease, and two were non-
responders. 
For the entire series of 82 patients, 5-year recurrence-free
and overall survival were 72% and 77%, respectively. 
The seven patients who died of concurrent disease with no
evidence of tumor were not included in the subsequent survival
analyses. Among the remaining 75 patients, 5-year recurrence-
free and overall survival were 77% and 84%, respectively.
Recurrence-free and overall survival by univariate analysis
are shown in Table III.
The patients who achieved an optimal response or sub-
optimal response with intra-cervical residual disease had
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Table II. Recurrence rates and sites according to postoperative treatment.
                                                                                                                                                    Site of recurrence, n
Postoperative treatment                                                                      Patients, n         Pelvic          Extrapelvic        Pelvic + extrapelvic         Overall, n
Optimal responders (n=10)
  Chemotherapy                                                                                          5                    0                       0                                0                               0
  BCT                                                                                                          2                    1                       0                                0                               1
  No further treatment                                                                                3                    0                       0                                0                               0
Suboptimal responders with intracervical disease (n=36)
  Chemotherapy                                                                                          5                    1                       0                                0                               1
  CCRT or EBRT±BCT                                                                            15                    2                       0                                1                               3
  BCT                                                                                                          1                    0                       0                                0                               0
  No further treatment                                                                              15                    1                       0                                0                               1
Suboptimal responders with extracervical 
disease or non-responders (n=36)
  Chemotherapy                                                                                          2                    0                       0                                0                               0
  CCRT or EBRT±BCT                                                                           32                    7                       5                                0                             12
  No further treatment                                                                                2                    0                       0                                1                               1
BCT, Brachytherapy; CCRT, concurrent chemotherapy and radiotherapy; EBRT, external beam radiotherapy.
Table III. Variables predictive of 5-year recurrence-free survival (RFS) and overall survival (OS) by univariate analysis.
Variable                                                                                        Patients, n                RFS rate                  p-Value               OS rate                 p-Value
Age 
   ≤46 Years                                                                                          42                          76%                        0.902                    84%                     0.697
   >46 Years                                                                                          33                          76%                                                    83%
FIGO stage
   Ib2-IIa2                                                                                            59                          76%                        0.477                    83%                     0.195
   IIb                                                                                                     16                          78%                                                    86%
Tumor diameter*
   ≤5 cm                                                                                                36                          77%                        0.190                    85%                     0.537
   >5 cm                                                                                                32                          84%                                                    84%
Histological grade**
   G1-G2                                                                                               32                          76%                        0.179                    97%                     0.051
   G3                                                                                                     32                          69%                                                    70%
Chemotherapy regimen 
   TEP                                                                                                  51                          73%                        0.455                    82%                     0.391
   Other                                                                                                 24                          86%                                                    90%
Pathological response 
   Optimal+suboptimal intra-cervical residual                                   43                          87%                        0.017                    92%                     0.012
   Suboptimal extra-cervical residual/no response                             32                          64%                                                    74%
Radical hysterectomy
   Type 3                                                                                               60                          79%                        0.212                    89%                     0.082
   Type 2                                                                                               15                          67%                                                    66%
G1, Well-differentiated; G2, moderately differentiated; G3, poorly differentiated; TEP, paclitaxel+epidoxorubicin+cisplatin. *Data available on 68
patients; **data available on 64 patients.
better 5-year recurrence-free (87% versus 64%, p=0.017;
Figure 1) and overall (92% versus 74%, p=0.012; Figure 2)
survival than those who had sub-optimal response with extra-
cervical residual disease or no response. The TEP regimen
gave no benefit compared with two-drug regimens. 
On multivariate analysis, pathological response to NACT
was an independent prognostic variable for both recurrence-
free survival (Wald χ2=7.336, HR=1.441, 95% CI=1.106-
1.877, p=0.007) and overall survival (Wald χ2=9.965,
HR=1.652, 95% CI=1.210-2.256, p<0.002). 
Discussion
Platinum-based NACT followed by radical hysterectomy has
obtained good results in stage Ib2-IIb squamous cell
carcinoma of the uterine cervix (6-8,11,13-15), whereas few
data are currently available about the efficacy of this chemo-
surgical treatment in cervical adenocarcinoma, with clinical
overall response rates ranging from 50% to 93% (34, 36-42)
(Table IV). Pooled data from three consecutive trials using
different regimens showed a 5-year overall survival rate of
84% in the 33 responding patients, whereas all 9 non-
responders died after a median of 10 months (p<0.0001) (36).
The clinical response to NACT was the only independent
prognostic variable for survival. Radical hysterectomy was
feasible in 29 of the responding patients, and a complete
response was detected in 10% of them. Zanetta et al. reported
a clinical overall response rate of 67% among 21 patients
who received at least four cycles of NACT. Eighteen of them
underwent surgery and hysterectomy specimen showed the
persistence of microscopic disease in four (19%) and
macroscopic disease in 14 (37). 
In the study of Iwasaka et al., 12 patients with stage Ib-II
disease underwent radical hysterectomy after NACT and the
mean survival was 47.5 months for responders and 28.3
months for non-responders. Conversely, all four patients with
more advanced disease, who were treated with radiotherapy
or second-line chemotherapy, died of disease after a median
of 10 months (38).
The pathological examination of surgical specimens of 14
patients treated with NACT and radical hysterectomy by Tabata
et al. revealed no residual disease in six patients and
microscopic residual disease <5 mm in two, with a
pathological optimal response rate of 57% Optimal responders
experienced a longer overall survival compared to patients with
macroscopic residual disease (p=0.012) (39).
In a phase II Japanese study, 50 (96%) out of 52 patients
underwent radical hysterectomy after NACT. The 2-year
overall survival was 82% for stage Ib2, 86% for stage IIa2,
and 93% for stage IIb (42). 
Shoji et al. achieved a clinical overall response in 78% of
23 patients scheduled for radical hysterectomy. Surgery was
completed in 18 patients whose median progression-free and
overall survival were 26 months and 35 months, respectively.
Conversely, all five patients in whom surgery was not
complete died of tumor within 35 months (41). 
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Figure 1. Recurrence-free survival by pathological response. Figure 2. Overall survival by pathological response.
In the retrospective study of Hu et al., the pathological
examination of surgical specimens showed complete
disappearance of tumor or residual tumor with less than 3 mm
stromal invasion in 15% of 62 patients with cervical
adenocarcinoma who underwent surgery following NACT (34). 
The results of the present retrospective investigation,
including 82 patients treated in four Italian gynecological
oncological centers, compared favorably with literature data
in terms of clinical response rate, recurrence-free survival and
overall survival. The pathological optimal response rate was
similar to that of Hu et al. (34), Benedetti Panici et al. (36),
and Zanetta et al. (37) and was lower than that reported by
Tabata et al. (39). However, the latter Japanese study analyzed
only 14 patients and included patients with microscopic
residual disease <5 mm among optimal responders, whereas
in our investigation, optimal partial response was defined as
persistent residual disease with <3 mm stromal invasion
including in situ carcinoma. In the present study, disease
recurred in 23% of the patients after a median of 12.5 months,
and the pelvis was the most frequent site of failure. Extra-
pelvic relapse, with or without pelvic failure, was detected in
0%, 20%, and 46% of optimal responders, sub-optimal
responders with intra-cervical residual disease, sub-optimal
responders with extra-cervical residual disease or non-
responders, who developed recurrent disease, respectively. 
He et al. reassessed two randomized trials and nine
observational studies, including a total of 1,559 patients, to
determine whether the efficacy of NACT was different between
those with squamous cell carcinoma and those with
adenocarcinoma/adenoquamous carcinoma of the uterine
cervix (44). No difference in terms of either overall response
rate or complete response rate was found between those with
squamous and non-squamous carcinomas, whereas the long-
term outcome in terms of overall survival and progression-free
survival was better for those with squamous cell carcinomas.
However, we must take into consideration that adenocarcinoma
of the uterine cervix has a wide histopathological spectrum and
that it can be classified into seven subtypes (45, 46). No
meaningful clinical data are currently available on the
sensitivity to chemotherapy of each single subtype. 
Some authors reported that clinical response (36, 38) or
pathological response (39) to NACT had a relevant impact on
survival. In the present investigation, the patients who
achieved a pathological optimal response or sub-optimal
response with intra-cervical residual disease had a
significantly better 5-year recurrence-free (87% vs. 64%,
p=0.017) and overall ( 92% vs. 74%, p=0.012) survival than
those who had a sub-optimal response with extra-cervical
residual disease or no response. These latter had a 1.441-fold
higher risk of recurrence and a 1.652–fold higher risk of death
for tumor than those who obtained an optimal response or sub-
optimal response with intra-cervical residual disease.
The number of patients analyzed in retrospective studies
on chemo-surgical treatment in cervical adenocarcinoma
ranges from 14 to 62. The strengths of the present
investigation are represented by the fairly large number of
patients of an uncommon clinical scenario, the long-term
follow-up, and the accurate reporting of the pattern of
recurrence. Similarly to a prior study of our cooperative
group on 333 patients with squamous or non-squamous
cervical carcinoma treated with NACT and radical surgery
(16), the weaknesses of this investigation are mainly
represented by its retrospective design, the lack of control
group, the variety of adjuvant treatment, changing use of
chemotherapy, the 20-year study period, and the lack of data
on patients who dropped out. 
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Table IV. Clinical response rate to platinum-based neoadjuvant chemotherapy (NACT) in patients with adenocarcinoma of the uterine cervix.
Author (Ref)                                        Patients, n        Stage                                     NACT regimen                                 CR, n          PR, n            OR,%
Benedetti et al. (36)                                  42            Ib2-IIIB                                Different regimens                                   3                30               79%
Zanetta et al. (37)                                     21             Ib2-IIb                            50 mg/m2 CDDP weekly                              4                10               67%
                                                                                                                      70 mg/m2 EPIDX weeks 1, 4, 7                          
Iwasaka et al. (38)                                    16               Ib-IV            50 mg/m2 CDDP d1 + 10 mg/m2 MIT-C d1 +            3                  5               50%
                                                                                                              100 mg/m2 VP-16 d1, 3, 5 every 4 weeks
Tabata et al. (39)                                       14             Ib1-IIb                   15 mg/m2 CDDP d 1-5 + 15 mg/m2                    7                  6               93%
                                                                                                                MIT-C d1 + 70 mg/m2 VP-16 d 1-3, + 
                                                                                                                  30 mg/m2 EPIDX d1 every 4 weeks
Shimada et al. (42)                                   52             Ib2-IIb        DOC 60 mg/m2 + CBDCA AUC5 every 3 weeks          5                31               69%
Shoi et al. (41)                                          23             Ib2-IIb                 175 mg/m2 PTX or 70 mg/m2 DOC +                   5                13               78%
                                                                                                                       CBDCA AUC6 every 3 weeks
Hu et al. (34)                                             67             Ib1-IIb                     Different cisplatin-based regimen                     10                43               79%
Present series                                             82             Ib2-IIb                     Different platinum-based regimen                       9                58               82%
CR, Complete response; PR, partial response; OR, overall response; CDDP, cisplatin; EPIDX, epidoxorubicin; MIT-C, mitomycin-D; VP-16,
etoposide; DOX, docetaxel; CBDCA, carboplatin; AUC: area under receiver operating characteristics curve; PTX, paclitaxel.
In conclusion, our data showed that platinum-based
NACT followed by radical hysterectomy may be an option
for patients with stage Ib2-IIb adenocarcinoma of the uterine
cervix. 
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